Solventum

“largely from the wind-down of transition services agreements related to Solventum”

3M is winding down the transition services agreements tied to its former spinoff Solventum, a modest drag on 3M corporate income as that separation relationship runs off.

“we completed the acquisition of our filtration and separation business from Solventa.”

Thermo Fisher acquired the filtration and separation (purification) business divested by Solventum, a read-through on Solventum shedding that unit.

“we completed our acquisition of our filtration and separation business from Solventum, which is now part of our Life Sciences Solutions segment”

Thermo Fisher closed its acquisition of Solventum's filtration and separation business (~$750M revenue), expanding its bioprocessing and industrial filtration offering.

“in February, we announced that we had entered into a definitive agreement to acquire Solventum's Purification & Filtration business. Last month, we amended our agreement to remove Solventum's drinking water filtration business from the transaction, which allowed us to both accelerate the regulatory clearance process and narrow the scope of the acquisition to the business lines most synergistic with Thermo Fisher.”

Thermo Fisher is acquiring Solventum's Purification & Filtration business, having narrowed the deal scope by removing the drinking water filtration unit to accelerate regulatory clearance; the deal is on track to close before year-end.

“In February, we announced that we entered into a definitive agreement to acquire SOVENTUM's purification and filtration business for $4.1 billion. The business is a leading provider of filtration technologies used in the production of biologics, as well as in medical technologies and industrial applications.”

Thermo Fisher is acquiring Solventum's purification and filtration business for $4.1 billion, expected to close by year-end 2025, broadening Thermo's bioprocessing capabilities.

“This performance was driven by benefits from volume leverage, productivity, Solventum transition service agreement, cost reimbursements, and restructuring, partially offset by FX and investments to drive growth in the business.”

3M's full-year margin expansion was aided by transition service agreement cost reimbursements from Solventum, an ongoing financial benefit tied to the spinoff.

“Earlier in the year, we spun off our Healthcare Business Group as Solventum and we settled two significant legal matters.”

3M frames the 2024 spinoff of its Healthcare Business Group as Solventum as a completed structural milestone for the transition year.

“we announced and closed our first tuck-in acquisition, Acera Surgical, which not only opens the door to the fast growth synthetic tissue market, it also very well complements our existing technology categories and our call points.”

Solventum's acquisition of Acera Surgical adds a differentiated, profitable double-digit grower in the synthetic tissue market to its Advanced Wound Care business.

“3M gave themselves a contractual option to again step up our cost in 2027, and we've shared that, that's about a 100 basis point headwind for us if that in fact happens.”

3M holds a contractual option to raise the raw-material costs it charges Solventum in 2027, a potential ~100bp margin headwind; the companies are discussing an alternative.